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ABSTRACT
Objective: The objective of this selective evidence based medicine (EBM) review is to
determine whether or not ranibizumab improves best corrected visual acuity (BCVA) in adults
with diabetic macular edema compared to patients who do not receive ranibizumab
Study Design: The selective review examined best corrected visual acuity values reported from
published, primary literature sources that examined the efficacy of ranibizumab in diabetic
macular edema
Data Sources: Two double blind randomized controlled trials and one case control study were
selected and reviewed
Outcomes Measured: Best corrected visual acuity (BCVA) as measured from Early Treatment
Diabetic Retinopathy Study visual acuity charts, which were converted to dichotomous data to
determine treatment effects. Adverse events were also considered in this selective review to
determine safety of this therapeutic intervention.
Results: Mean BCVA improvements were 10.3, 9, and 13 with all p-values < 0.05 compared to
statistically significant decline in acuity in control arms. Adverse event rates were notably higher
in therapeutic arms but only a minority was serious adverse events (SAE).
Conclusion: All reported increases in BCVA suggests that indeed ranibizumab is an effective
therapeutic option for diabetic macular edema but requires continued investigation to further
elaborate its safety profile outside a controlled research setting

Key Words: Ranibizumab, Lucentis, diabetic macular edema, diabetic retinopathy, macular
edema, VEGF inhibitors
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Diabetic macular edema (DME) is a common manifestation of diabetic retinopathy,
causing blurred vision due to the edema of the macula. In a diabetic patient, poorly controlled
hyperglycemia triggers several cascades of pathologic mechanisms. One such pathway both
induces the apoptosis of pericytes that surround retinal vessels as well as thickens the basement
membrane of the very same vessels, which allows microaneurysms to occur and the leaking of
plasma in the retinal layers to include the macula. Though the eye is capable of tolerating a
certain volume of leaked fluid in the retina, hyperglycemia and retinal ischemia also trigger the
release of vascular endothelial growth factor (VEGF). VEGF is a key signaling protein that
promotes a pathologic angiogenesis; the body increases the vasculature in the retina, which is
prone to the same microaneurysms and leaking. A combination of neovascularization and porous
vessels leads to the rapid accumulation of plasma fluid, leading to diminishing visual acuity.
Epidemiology
Diabetes mellitus and its complications have a regrettably high impact and prevalence in
the United States; therefore physician assistants will undoubtedly encounter, diagnose, and treat
this disease. In 2010, the CDC estimated that approximately 25.8 million individuals suffered
from diabetes mellitus in the United States.1 Of these diabetics, nearly 100% of type 1 diabetics
and approximately 60% of type 2 diabetics are projected to develop diabetic retinopathy over the
course of 15 to 20 years.2 In light of its incidence, it is imperative for physician assistants and
other healthcare providers to prepare themselves to be able to identify and treat this condition
accurately and effectively.
Likewise, diabetic retinopathy has a significant impact on the patient and social welfare
programs. In a study comparing Medicare reimbursements to diabetics without and with macular
edema, the investigators found that Medicare paid an additional $2,892 per Medicare beneficiary
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with diabetic macular edema within the first year of diagnosis.3 At three years following the
diagnosis, Medicare reimbursed on average an additional $8,312 per Medicare beneficiary with
diabetic macular edema.3 While the cost to the federal government is clear, it may also be
surmised that the cost to the patient rises as well with co-pays, deductibles, and associated
logistical costs (e.g. transportation).
Diabetic retinopathy also substantially affects the time spent by both provider and patient.
In another study examining the impact of this manifestation of diabetic retinopathy, it was
estimated that patients with diabetic macular edema have three times more ophthalmologic visits
than those who do not, with approximately 3.9 visits per year.4 With an estimated prevalence of
2 million suffering diabetic retinopathy in the United States2, this comes out to approximately 8
million healthcare visits in the United States per year.
Current & Future Therapies
With the impact of diabetic retinopathy & macular edema established, the logical
questions to investigate are what is known about the disease and what can be done to combat it.
As described earlier, much is already known about the etiology and pathophysiology of diabetic
macular edema; however the elusive piece of the puzzle is curative therapy.
Current therapies focus on glycemic control and focal laser photocoagulation. Tight
glycemic control in patients with diabetes mellitus is the most effective therapy, but this efficacy
is lost as retinopathy progresses to advanced stages. This leaves focal laser coagulation as the
mainstay of therapy for diabetic macular edema. Unfortunately this therapy is far from ideal;
patients undergoing the procedure may expect a modest improvement in best corrected visual
acuity (BCVA) by 30%, and up to 20% of those who receive laser photocoagulation will
experience a worsening of their vision.1
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The risks and limited efficacy of focal laser photocoagulation has driven the search for a
more effective therapy that can help restore visual acuity in patients with diabetic macular edema.
Ranibizumab (trade name Lucentis) is a result of such research. Ranibizumab is a monoclonal
antibody, which inhibits VEGF-A and thereby prevents the angiogenesis of excessive, weak
vasculature that would otherwise leak plasma into the retinal layers & macula. It is among the
first generation of promising treatments that may help restore vision in those with diabetic
macular edema but is also relatively new and requires further examination.
OBJECTIVE
Therefore the objective of this selective review is to determine whether or not
ranibizumab improves BCVA in adults with diabetic macular edema.
METHODS
Criteria
To examine this question, this paper focuses on adults (age ! 18 years old) with a
diagnosis of diabetic macular edema. Interventions that were considered in a literature search
included intravitreal injections of ranibizumab, placebo injections, and focal laser
photocoagulation, provided the study had at least one arm including ranibizumab as an
intervention and one without. The quantifiable, objective outcome used was BCVA as assessed
through the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity chart. Types
of studies considered were randomized controlled trials; however one study that was selected and
included in data analysis was a case control study.
Data Sources
A search of English-language published, primary literature was performed through
various, reputable search engines to include MedLine, PubMed, and Ovid. Key words used in the
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search included: Lucentis, ranibizumab, diabetic macular edema, and diabetic retinopathy. A
Cochrane systematic review regarding the efficacy of ranibizumab on visual acuity in diabetics
with macular edema was found dating 2009; therefore only articles published following this date
were considered in this review as part of the inclusion criteria. Exclusion criteria included the
effects of ranibizumab on other similar ophthalmologic pathologies and studies using subjective
metrics to gauge the efficacy of this novel monoclonal antibody.
Ultimately, three studies were selected: a double-blind randomized controlled trial
conducted by Massin et al in 2010 (i.e. the RESOLVE study)5, another double-blinded
randomized controlled trial conducted by the Diabetic Retinopathy Clinical Research Network
(DRCRN) in 20106, and a case control study led by Ozturk et al in 2011.7
Massin et al published the findings of a multicenter, phase II clinical trial on ranibizumab
on its safety and efficacy on study participants with diabetic macular edema. The study was
designed as a double-blinded, randomized control trial. The investigators randomized subjects
into three arms: 0.3 mg intravitreal injections, 0.5 mg intravitreal injections, and sham treatment
as the control group; they then measured best corrected visual acuity in their subjects at various
time points to include 12 months following treatment. The study was selected for its quality
design and large sample size from different sites.
The 2010 DRCRN study was a multicenter phase III clinical trial conducted as a doubleblinded, randomized controlled trial. The investigators compared the following interventions in
the study: (1) sham intravitreal injection followed by prompt (within 3-10 days of injection) focal
laser photocoagulation; (2) 0.5 mg ranibizumab injection followed by prompt focal laser
photocoagulation; (3) 0.5 mg ranibizumab injection followed by deferred (! 24 weeks) focal
laser photocoagulation; and (4) 4 mg triamcinolone injection followed by prompt focal laser
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photocoagulation. Though this selective review seeks to compare treatment of ranibizumab in
those suffering diabetic macular edema with those who do not receive it, it was decided that only
the first two interventions listed were truly comparable to be able to better attribute therapeutic
effect (if any) of ranibizumab compared to placebo. Follow up was performed both at 1 year and
3 years following treatment. To ensure maximal consistency with the RESOLVE study, data
points from the 1-year mark was examined in this review. This too was selected for its quality
design and large sample size from different sites.
Ozturk et al performed a case control study examining the clinical records of patients
with diabetic macular edema who received either ranibizumab or bevacizumab (a similar VEGF
inhibitor) and compared improvement in BCVA. The study encompassed 29 eyes of 29 patients,
and these patients received either 0.5 mg ranibizumab intravitreal injection or a 1.25 mg
bevacizumab intravitreal injection. Both Snellen charts and ETDRS visual acuity charts were
used to assess improvements in patient’s vision. Due to the limited number of quality studies
following 2009, this study was selected not only for its quality but its consistency in measuring
outcomes following administration of ranibizumab.
Both the RESOLVE study and the 2010 Diabetic Retinopathy Clinical Research Network
study reported mean changes in BCVA with 95% confidence intervals and its associated pvalues. The RESOLVE study further reports relative risk values associated with the gain or loss
of letters in BCVA. Ozturk et al reported mean & median changes as BCVA values with
associated p-values.
Information regarding the inclusion and exclusion criteria as well as specific
interventions of the selected studies is summarized in Table 1.

Double-blind,
randomized
control trial

Case control
study

Diabetic
Retinopathy
Clinical Research
Network (2010)

Ozturk et al (2011)

29

691

56.18 ± 13.07

63 ± 10

• Patients with type 1 or 2 diabetes mellitus (DM)
• Age " 18 years old
• Received only 1 dose injection of bevacizumab and
did not attend the scheduled repeated intravitreal
bevacizumab injection regimen OR
• Among them, patients who visited the retina service
after at least 6 months and planned to receive
monthly intravitreal ranibizumab injection for DME

• Best-corrected ETDRS visual acuity of 24 to 78
• Retinal thickening due to DME involving the center
of the macula AND assessed to be the main cause
of visual loss
• Retinal thickness "250 µm

Table 1: Demographics and Characteristics of Included Studies
No. of
Study
Type
Age
Inclusion Criteria
Participants
Massin et al (2010) Double-blind, 151
63.6
• Age >18 years
randomized
• Type 1 or type 2 diabetes mellitus
control trial
• Hb A1C levels that have not substantially fluctuated
and are !12%
• DME with center involvement in at least one eye
Withdrawn
from Study
19

• Application of any other intravitreal drug injection
elsewhere during the study period
• Panretinal, grid, or focal laser photocoagulation
within 6 months of studied intervention
• Presence of any other macular pathology
• Any associated pathology requiring laser or
surgical treatment
• Intraocular surgery within 6 months of studied
intervention
• Intravitreal drug injection to the other eye not
examined in the research within 6 months of study
internvention
• Did not attend the first 3 control visits.

0

• Treatment for DME within the prior 4 months prior 44
to recruitment into the study
• Panretinal photocoagulation within the prior 4 mos
or anticipated need within next 6 mos
• Major ocular surgery within the prior 4 mos
• Hx of open-angle glaucoma or steroid-induced IOP
elevation
• IOP "25 mmHg.
• SBP >180 mmHg or DBP >110 mmHg
• Any cardiac event requiring hospitalization within 4
months before randomization

• Panretinal, focal peripheral laser photocoagulation
within 6 mos
• Previous grid/central laser photocoagulation (with
exceptions)
• Proliferative diabetic retinopathy in the study eye
(with exceptions)
• Unstable medical conditions (with exceptions)
• Systemic corticosteroids within 4 mos
• Use of corticosteroids more than 2 / week
• Previous participation in a study on anti-angiogenic
drugs
• Any condition that may introduce confounding
factors
• Any condition that puts prospective subjects at
substantial risk from the studied intervention
• Ocular inflammation in either eye or history of
cataract surgery in the study eye within 6 mos
• Women of childbearing age without sufficient use
of contraceptives, pregnant or nursing women

Exclusion Criteria

Monthly intravitreal injections of ranibizumab at 0.3
mg OR 0.5 mg OR sham treatment (pressure with
blunt tip of syringe against anesthetized eyes.

• Sham injection plus prompt focal/grid
photocoagulation
• Intravitreal ranibizumab plus prompt focal/grid
photocoagulation
• Intravitreal ranibizumab with deferred focal/grid
photocoagulation
• Intravitreal triamcinolone plus prompt focal/grid
photocoagulation

Monthly intravitreal injections of ranibizumab
(Lucentis™) at 0.3 mg OR 0.5 mg OR sham
treatment (pressure with blunt tip of syringe against
anesthetized eyes.

Intervention(s)
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OUTCOMES MEASURED
As previously stated, best-corrected visual acuity was measured in all three selected
studies with the ETDRS visual acuity chart, an instrument that is similar to the Snellen chart and
is used in clinical research assessing visual acuity. The chart, designed by Ferris et al in 19828,
has become the gold standard in assessing visual acuity in clinical research studies9 and defines
with greater resolution the subtle differences of visual acuity that cannot be captured by the
Snellen chart. This metric, known as BCVA, uses the total number of letters that a research
subject can read in order to gauge their visual deficit. It can be read from a variety of distances
depending on the size of the chart itself. As previously stated, best corrected visual acuity
(BCVA) was the outcome measured in each of the three selected studies. In the RESOLVE study,
investigators assessed BCVA of study participants at baseline, 1 month, and 12 months post
treatment. Similarly, the 2010 Diabetic Retinopathy Clinical Research Network study and Ozturk
et al had participants do the same with the ETDRS visual acuity chart.
RESULTS
Efficacy
In the RESOLVE study, at 12 months, the mean BCVA was 10.3 ± 9.1 letters improved
from the baseline in patients receiving ranibizumab injections versus the 1.4 ± 14.2 letter decline
in the control group (p<0.0001). For analysis purposes, continuous data was converted to
dichotomous data, and a minimum improvement of 10 letters or more was considered therapeutic
improvement in vision. Again at 12 months, 60.8% of individuals receiving the investigated drug
experienced this level of improvement compared to the 18.4% of the control group experiencing
this improvement. These values demonstrate a clear efficacy of the investigational new drug in
the improvement of best corrected visual acuity.
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The authors of the DRCRN study also reported treatment effects as continuous data,
which was converted to dichotomous data for this selective review. Mean change in BCVA in
study participants receiving ranibizumab and prompt photocoagulation at 12 months was a gain
in 9 ± 11 letters while those in the control arm experienced a gain of 3 ± 13. The difference in
mean change was reported to be a range of +3.2 to +8.5 with intravitreal ranibizumab injections
at a 95% CI (p < 0.001). When comparing efficacy of ranibizumab versus control in the two
prompt photocoagulation arms, approximately 50.8% of diabetics receiving ranibizumab enjoyed
a 10 letter or more increase in BCVA compared to the 27.6% among the control group. Though
both arms received focal photocoagulation, the relative benefit increase (RBI) clarifies the
proportional effect of ranibizumab at an 84.1% increase. Additional figures on treatment effects
follow in Table 2.
Ozturk and his colleagues performed a case control study, providing less substantial but
nonetheless meaningful data. The study found pretreatment mean score to be 52.29 ± 17.76 and
posttreatment scores to be 60.52 ± 18.44, with a median improvement from 53 to 66 (p < 0.001).
Table 2: Treatment Effects of Ranibizumab Injections in Diabetic Macular Edema Assessed by BCVA
STUDY
RESOLVE Study
2010 Diabetic Retinopathy
Clinical Research Network
Study
2011 Ozturk et al*

CER (%)
18.4

EER (%)
60.8

ABI (%)
42.4

RBI (%)
230

NNT (n)
2.36 ! 3

27.6

50.8

23.2

84.9

4.31 ! 5

n/a

n/a

n/a

n/a

n/a

* Data from case control study with limited results. Median BCVA improvement from 53 to 66 (p < 0.001)

Safety
As previously stated, the RESOLVE study also examined the safety profile of
ranibizumab in study participants differentiating serious adverse events (SAE) and adverse
events (AE) with subgroups of ocular events versus non-ocular events. Approximately 3.9% of
subjects randomized into ranibizumab injections experienced ocular SAE (e.g. vitreous
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hemorrhage) versus the 0% among those in the control arm. Seventy-eight (78.4) percent of
study participants in the ranibizumab arms experienced ocular AE (i.e. eye pain, conjunctival
hemorrhage, and increased intraocular pressure); fifty-seven percent of those in the control arm
experienced the same ocular AE. Non-ocular AE and SAE demonstrated similar trends with a
likelihood of these events to occur with those receiving ranibizumab. It should be noted that the
investigators did not attribute all reported SAE & AE to the effects of the drug (e.g. only 60.7%
experienced ocular AE attributed to ranibizumab by the investigators in contrast to the reported
total 78.4 %). Additional harm effects are reported along with those of the other selected studies
in Table 3.
With regard to safety in the 2010 DRCRN study, the investigators found no difference in
the frequency of systemic, nonocular adverse events and serious adverse events; therefore only
ocular AE & SAE are considered and examined in this review. The investigators also did not
differentiate between an AE and SAE and, as in other studies, counted the number of events as
opposed to the number of individuals experiencing these deleterious effects thereby altering the
calculated RRI, ARI, and NNH. These calculated values, seen in Table 3, actually show negative
values suggesting that ranibizumab intravitreal injections would actually reduce risk and harm to
subjects without them.
Safety and adverse events were not addressed in the study conducted by Ozturk et al.
Table 3: Harmful Effects of Ranibizumab Injections in Diabetic Macular Edema Assessed by AE / SAE
STUDY
RESOLVE Study
(Ocular SAE)
RESOLVE Study
(Ocular AE)
2010 Diabetic Retinopathy
Clinical Research Network
Study (Ocular AE & SAE)
2011 Ozturk et al†

CER (%)

EER (%)

ARI (%)

RRI (%)

NNH (n)

0

3.9

3.9

n/a

25.6 ! 26

57.1

78.4

21.3

37.3%

4.69 ! 5

31

21

-32.3

-10

-10

n/a

n/a

n/a

n/a

n/a

† Adverse events not assessed or studied in this investigation
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DISCUSSION
Before conclusively addressing whether or not ranibizumab is indeed effective restoring
diminished sight in diabetics with macular edema, it is worthwhile to consider its flaws. For
example, it should be noted that the two randomized controlled trials demonstrate the distinct
possibility of worsening visual acuity. The RESOLVE study demonstrated that at least 7.8%
experienced worsening visual acuity; the 2010 DRCRN study reported up to an 11% in subjects
receiving ranibizumab and prompt focal photocoagulation. In clinical practice, these numbers
may be high enough to warrant a great degree of caution in considering this treatment.
There are additional considerations to using ranibizumab as treatment for diabetic
macular edema. During the analysis and writing of this selective review, the FDA recently
approved its indication in the treatment of diabetic macular edema on 10 August 201210;
therefore its novelty and projected length of time being on patent is likely to keep the price high.
As of 2006, a 0.5 mg dose of ranibizumab (wholesale price) cost $1,950 and likely has not
changed substantially.11 The FDA indication is for 0.3 mg per month, which would likely cost
approximately $1,170. Although Genentech attempts to mitigate cost, it may be some time
before health insurance companies become willing to cover any portion of these astronomical
costs for its plan participants.
Ranibizumab also faces a competitor from the same manufacturer, bevacizumab (trade
name Avastin) yet another VEGF inhibitor. Although the FDA does not approve its use in
diabetic macular edema, studies such as the aforementioned Ozturk et al investigation have
explored its off-label use with similar efficacy. Its cost ($17 to $50 per injection) also makes it
substantially more appealing to prescribing practitioners.11 As it stands, ranibizumab does not
lack challenges in its future as a therapeutic option for diabetic macular edema.

Huang - Ranibizumab & Diabetic Macular Edema

11

CONCLUSION
Having considered the results of these studies and limitations of the drug itself, this
selective EBM review concludes that ranibizumab is indeed effective in improving best corrected
visual acuity in diabetic macular edema. This monoclonal antibody is not absolutely benign nor
is it reasonably affordable by most individuals in the United States, but since curative therapy is
lacking, ranibizumab and similar medications may represent the promise of eventual restored
sight and pave the way for future generations of similar therapies.
The future direction of research will likely involve improved and more efficient means of
engineering and compounding the medication in a manner that reduces costs and improves its
safety profile since monoclonal antibody therapy remains costly,13 which may prohibit patients
and providers from accessing this effective therapeutic agent. Such research would fall under the
purview of biomedical and biomedical engineering research to find cheaper methods of
compounding and mass-producing ranibizumab.
Concurrent research should expand the inclusion criteria of previous clinical research
studies and to begin minimizing exclusion criteria to establish a clearer safety profile. Since
patients with diabetic macular edema will likely have other comorbidities, conducting clinical
research in these populations with other chronic pathologic processes will clarify the boundaries
in which providers may prescribe and administer this therapy. Until such research is complete, its
use must be carefully monitored to ensure an efficacy consistency with prior phase II & III trials
as well as fully determine its true safety profile as it is used outside a controlled setting.
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